Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4722)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 28, 2024 (publication date) through Dec 9, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Lu R, Zhang M, Liu ZH, Hao M, Tian Y, Li M, Wu FP, Wang WJ, Shi JJ, Zhang X, Jia XL, Jiang ZC, Li XM, Xu GH, Li YP, Dang SS. Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens. World J Gastroenterol 2024; 30(44): 4725-4737 [PMID: 39610775 DOI: 10.3748/wjg.v30.i44.4725] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Lu R, Zhang M, Liu ZH, Hao M, Tian Y, Li M, Wu FP, Wang WJ, Shi JJ, Zhang X, Jia XL, Jiang ZC, Li XM, Xu GH, Li YP, Dang SS. Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens. World J Gastroenterol 2024; 30(44): 4725-4737 [PMID: 39610775 DOI: 10.3748/wjg.v30.i44.4725] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i44/4725.htm |
| Number | Citing Articles |
| 1 |
Li-Jun Chang, Chun-Qiu Hao, Gui-Rong Rao, Lin-Li Xu, Jing Li, Yan Cheng, Li-Jun Zheng, Cun-Wen Wu, Han-Xian Chen, Ze-Ren Chen, Jian-Qi Lian, Shi-Hong Wu, Li-Min Luo, Wei-Lu Zhang, Ye Zhang. Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-α-2b-based therapy: a multicenter pilot study. Virology Journal 2025; 22(1) doi: 10.1186/s12985-025-02761-3
|
| 2 |
Jun Chen, Zebing Huang, Xueyao Yang, Yongwen Yang, Min Tan, Lihua Duan, Xuexuan Li, Shang Gao, Zhiliang Gao, Yan Huang. Predictors of Durable Hepatitis B Surface Antigen Loss After Pegylated Interferon–Based Therapy in Patients with Hepatitis B e Antigen–Negative Chronic Hepatitis B: A Multicenter Real-World Study. The Journal of Infectious Diseases 2025; 232(4): 953 doi: 10.1093/infdis/jiaf198
|
| 3 |
Ye Zhang, Yu Li, Jian-Qi Lian, Wen Kang. Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection. Drug Design, Development and Therapy 2025; : 10411 doi: 10.2147/DDDT.S564254
|
| 4 |
Yong-Hong Wang, Ya-Chao Tao, Meng-Lan Wang, Cheng-Run Song, Jiang-Nan Peng, En-Qiang Chen. Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study. Journal of Virus Eradication 2025; 11(4): 100617 doi: 10.1016/j.jve.2025.100617
|